Alzheimer’s marks fourth late-stage miss for Biohaven’s glutamate modulator 

Biohaven’s glutamate modulator troriluzole has missed its primary endpoint in a fourth neurological indication, this time Alzheimer’s disease. That won’t necessarily prevent the company from advancing the therapy.

Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) fell $7.08 to $77.83 Tuesday, losing $424 million in market cap, after reporting that troriluzole failed to meet its co-primary and secondary endpoints in a Phase II/III trial to treat Alzheimer's disease. ...